NCT06943521 - A Study of MT-4561 in Patients With Various Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 18, 2025

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2028

Conditions

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Esophageal CancerGastric CancerBiliary Tract CancerPancreatic Ductal Adenocarcinoma (PDAC)Breast CancerOvarian CancerCervical CancerEndometrial CancerProstate CancerUrothelial CarcinomaNeuroendocrine Tumor (NET)Neuroendocrine Carcinoma (NEC)Soft Tissue SarcomaNuclear Protein in Testis (NUT) Carcinoma

Interventions

DRUG

MT-4561

i.v.

Trial Locations (6)

43210

RECRUITING

The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus

49546

RECRUITING

START Midwest, Grand Rapids

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

90033

RECRUITING

University of Southern California, Los Angeles

104-0045

RECRUITING

National Cancer Center Hospital, Chuo-Ku

Unknown

RECRUITING

National Cancer Center Hospital East, City